PL3460052T3 - Ulepszone allogeniczne komórki dendrytyczne do stosowania w leczeniu nowotworu - Google Patents

Ulepszone allogeniczne komórki dendrytyczne do stosowania w leczeniu nowotworu

Info

Publication number
PL3460052T3
PL3460052T3 PL17192226T PL17192226T PL3460052T3 PL 3460052 T3 PL3460052 T3 PL 3460052T3 PL 17192226 T PL17192226 T PL 17192226T PL 17192226 T PL17192226 T PL 17192226T PL 3460052 T3 PL3460052 T3 PL 3460052T3
Authority
PL
Poland
Prior art keywords
dendritic cells
cancer treatment
allogeneic dendritic
improved
improved allogeneic
Prior art date
Application number
PL17192226T
Other languages
English (en)
Inventor
Alex Karlsson-Parra
Original Assignee
Immunicum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunicum Ab filed Critical Immunicum Ab
Publication of PL3460052T3 publication Critical patent/PL3460052T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
PL17192226T 2017-09-20 2017-09-20 Ulepszone allogeniczne komórki dendrytyczne do stosowania w leczeniu nowotworu PL3460052T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17192226.3A EP3460052B1 (en) 2017-09-20 2017-09-20 Improved allogeneic dendritic cells for use in cancer treatment

Publications (1)

Publication Number Publication Date
PL3460052T3 true PL3460052T3 (pl) 2020-05-18

Family

ID=59997072

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17192226T PL3460052T3 (pl) 2017-09-20 2017-09-20 Ulepszone allogeniczne komórki dendrytyczne do stosowania w leczeniu nowotworu

Country Status (11)

Country Link
US (1) US20200216806A1 (pl)
EP (1) EP3460052B1 (pl)
JP (1) JP2020533977A (pl)
CN (1) CN111094553A (pl)
BR (1) BR112020004221A2 (pl)
DK (1) DK3460052T3 (pl)
ES (1) ES2769128T3 (pl)
HU (1) HUE047540T2 (pl)
PL (1) PL3460052T3 (pl)
SI (1) SI3460052T1 (pl)
WO (1) WO2019057745A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
CA3013639A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2020227279A1 (en) * 2019-05-06 2020-11-12 Hasumi International Research Foundation Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors
WO2022061811A1 (zh) * 2020-09-27 2022-03-31 深圳华大生命科学研究院 药物组合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103707A1 (en) 2002-06-06 2003-12-18 Immunicum Ab New method and composition for producing a cellular allogeneic vaccine
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
US20100196336A1 (en) * 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
DK2534242T3 (en) 2010-02-10 2016-07-18 Immunicum Ab Improved composition for the inhibition of tumor cell proliferation
US9017672B2 (en) 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof
RU2668816C2 (ru) 2012-12-18 2018-10-02 Иммуникум Аб Совместная дифференцировка моноцитов от аллогенных доноров

Also Published As

Publication number Publication date
ES2769128T3 (es) 2020-06-24
JP2020533977A (ja) 2020-11-26
HUE047540T2 (hu) 2020-04-28
US20200216806A1 (en) 2020-07-09
DK3460052T3 (da) 2020-02-03
CN111094553A (zh) 2020-05-01
EP3460052B1 (en) 2019-10-30
EP3460052A1 (en) 2019-03-27
BR112020004221A2 (pt) 2020-09-08
SI3460052T1 (sl) 2020-03-31
WO2019057745A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
HK1244826A1 (zh) 用於過繼細胞治療的方法和組合物
IL251774A0 (en) Methods and preparations for dosing in stress cell therapy
HRP20180876T1 (hr) Adc duokarmicina, namijenjeni upotrebi u liječenju raka mokraćnog mjehura
EP3134115A4 (en) Methods and compositions for treating metastatic breast cancer and other cancers in the brain
SI3460052T1 (sl) Izboljšane alogene dendritične celice za uporabo pri zdravljenju raka
IL251630A0 (en) Combined therapy for use in cancer treatment
IL246607A0 (en) Improved cellular preparations and methods for cancer treatment
IL251905B (en) Epilimod for use in the treatment of kidney cancer
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
IL262656A (en) Nanoliposomal irinotecan for use in the treatment of small cell lung cancer
HK1256603A1 (zh) 靶向髓樣衍生的抑制細胞中的四跨膜蛋白33(tspan33)的癌症療法
IL251903A0 (en) Epilimod for use in the treatment of colon cancer
PL3253208T3 (pl) Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
IL271442A (en) Preparations and methods for treating cancer with dengue virus and dendritic cells
EP3145516A4 (en) Methods and compositions for treating malignancies with dendritic cells
IL262143A (en) Improvements in cancer treatment
IL255560A (en) Macrophinocytosis in cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
EP3645561A4 (en) COMPOSITIONS AND METHODS OF ADOPTIVE CELL THERAPY AGAINST CANCER
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
ZA201403006B (en) Composition for use in treatment of cancer